Form 4: Arcutis Biotherapeutics Executive Exercises Options and Sells Shares

Arcutis Biotherapeutics' Senior Vice President and Chief Medical Officer, Patrick Burnett, exercised stock options and sold shares on November 22, 2024.

Summary

• Patrick Burnett, Senior Vice President and Chief Medical Officer of Arcutis Biotherapeutics, exercised stock options to acquire 16,023 shares of common stock at a price of $0 on November 22, 2024.
• On the same day, Mr. Burnett sold 16,023 shares of common stock at a weighted average price of $10.1426 per share, with individual sales ranging from $10.14 to $10.205.
• Following these transactions, Mr. Burnett directly owns 128,669 shares of Arcutis Biotherapeutics common stock and 218,500 stock options.

Sentiment

Score: 5

Explanation: The document reflects a neutral event of an executive exercising options and selling shares. It is a routine transaction and does not indicate any positive or negative sentiment.

Industry Context

This is a routine filing related to insider transactions. It is common for executives to exercise stock options and sell shares, especially after vesting periods. These transactions are closely monitored by investors for insights into executive sentiment and potential future actions.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across the biotechnology industry.
• The vesting schedule of 1/48th monthly is a standard vesting schedule for stock options.
• The sale of shares at market price is a typical transaction for executives.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a small number of shares compared to the total outstanding shares.
• The transaction is a normal part of executive compensation and does not indicate any significant change in the company's outlook.

Key Dates

Keywords

Arcutis Biotherapeutics, stock options, insider trading, share sale, executive compensation, ARQT, Patrick Burnett